{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-038818","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2026-10-06T21:15:44+00:00","discovered_at":"2026-10-06T21:18:00.818461+00:00","generated_at":"2026-10-12T16:08:50.021955+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rocket Pharmaceuticals secures up to $150M credit facility from Hercules Capital; $35M drawn at close","bullets":["Credit facility with Hercules Capital provides up to $150M: $35M funded Sept 30, 2026; $20M and $15M available through mid-2027; $30M on Danon milestone; $50M subject to Hercules approval.","Interest at greater of prime or 6.75% plus 2.40%; interest-only through April 1, 2029, extendable to Oct 1, 2030 if FDA approves RP-A501 BLA for Danon disease; matures Oct 1, 2030.","Warrants issued to Lenders for up to 1,755,853 shares at $2.99/share; 409,699 exercisable after Tranche 1-A; fully exercisable only if $150M fully drawn.","Rocket had $283.7M cash as of June 30, 2026; with $35M initial draw, runway into Q3 2028; additional draws could extend into 2029.","Proceeds support pivotal Phase 2 study of RP-A501 for Danon disease and cardiovascular pipeline; CEO cites priority review voucher sale as diversifying capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-038818","json":"https://secwatch.observer/filing/0001140361-26-038818.json","markdown":"https://secwatch.observer/filing/0001140361-26-038818.md","text":"https://secwatch.observer/filing/0001140361-26-038818.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126038818/0001140361-26-038818-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126038818/ef20083350_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T16:08:50.021955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}